Stem-cell transplantation in T-cell non-Hodgkin's lymphomas

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1471-1477

  Hosing, C ^a   Champlin, R E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Review; Stem cell transplantation; T cell non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; DRUG MEGADOSE; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 79959719928     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr140     Document Type: Review

References (45)

1. Coiffier B, Brousse N, Peuchmaur M et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1990; 1: 45-50.
2. Schmitz N, Trumper L, Ziepert M et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116: 3418-3425.
3. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte GELA). Blood 1998; 92: 76-82.
4. Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 03: 2474-2479.
5. Escalon MP, Liu NS, Yang Y et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 005; 103: 2091-2098.
6. Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 2011 Jan 6 [Epub ahead of rint] doi:10.1093/annonc/mdq635.
7. Schetelig J, Fetscher S, Reichle A et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem ell transplantation. Haematologica 2003; 88: 1272-1278.
8. Rodriguez J, Conde E, Gutierrez A et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007; 78: 290-296.
9. Rodriguez J, Conde E, Gutierrez A et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007; 18: 652-657.
10. Feyler S, Prince HM, Pearce R et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone arrow Transplant 2007; 40: 443-450.
11. Kyriakou C, Canals C, Goldstone A et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 218-224.
12. Yang DH, Kim WS, Kim SJ et al. Prognostic factors and clinical outcomes of highdose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow ransplant 2009; 15: 118-125.
13. Corradini P, Tarella C, Zallio F et al. Long-term follow-up of patients with peripheral Tcell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem ell transplantation. Leukemia 2006; 20: 1533-1538.
14. Rodriguez J, Conde E, Gutierrez A et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study roup. Eur J Haematol 2007; 79: 32-38.
15. D'Amore F, Relander T, Lauritzen G et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral t-cell lymphomas (PTCLs)-overall and subtype-specific results of a phase II study from the Nordic Lymphoma Group 2009 Presented at the annual meeting of the European Hematology Association, Berlin. EHA (Abstr 53).
16. Mercadal S, Briones J, Xicoy B et al. Intensive chemotherapy (high-dose CHOP/ ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated atients with peripheral T-cell lymphoma. Ann Oncol 2008; 19: 958-963.
17. Reimer P, Rudiger T, Geissinger E et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin ncol 2009; 27: 106-113.
18. Jantunen E, Wiklund T, Juvonen E et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 004; 33: 405-410.
19. Gisselbrecht C, Lepage E, Molina T et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472-2479.
20. Mounier N, Gisselbrecht C, Briere J et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2004; 22: 2826-2834.
21. Al-Toma A, Verbeek WH, Visser OJ et al. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis 2007; 39: 34-641.
22. Bishton MJ, Haynes AP. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol 2007; 136: 111-13.
23. Sieniawski M, Angamuthu N, Boyd K et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem ell transplantation. Blood 2010; 115: 3664-3670.
24. Jagasia M, Morgan D, Goodman S et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 004; 45: 2261-2267.
25. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's ymphoma. N Engl J Med 1995; 333: 1540-1545.
26. Zamkoff KW, Matulis MD, Mehta AC et al. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant 2004; 33: 635-638.
27. Kewalramani T, Zelenetz AD, Teruya-Feldstein J et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006; 134: 202-07.
28. Kim MK, Kim S, Lee SS et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts urvival. Ann Hematol 2007; 86: 435-442.
29. Rodriguez J, Munsell M, Yazji S et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19: 3766-3770.
30. Blystad AK, Enblad G, Kvaloy S et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 7: 711-716.
31. Rodriguez J, Caballero MD, Gutierrez A et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 2003; 88: 1372-1377.
32. Smith SD, Bolwell BJ, Rybicki LA et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow ransplant 2007; 40: 239-243.
33. Rodriguez J, Caballero MD, Gutierrez A et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GELTAMO experience. Ann ncol 2003; 14: 1768-1775.
34. Rodriguez J, Conde E, Gutierrez A et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007; 92: 1067-1074.
35. Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological ubtype. Br J Haematol 2003; 120: 978-985.
36. Vose JM, Peterson C, Bierman PJ et al. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. Blood 990; 76: 424-431.
37. Fanin R, Ruiz de Elvira MC, Sperotto A et al. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999; 23: 437-442.
38. Oyama Y, Guitart J, Kuzel TM et al. High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003; 17: 1475-1483, xi.
39. Russell-Jones R, Child F, Olavarria E et al. Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival. Ann N Y cad Sci 2001; 941: 147-154.
40. Corradini P, Dodero A, Zallio F et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172-2176.
41. Wulf GG, Hasenkamp J, Jung W et al. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2005; 36: 271-273.
42. Kyriakou C, Canals C, Finke J et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 3951-3958.
43. Duvic M, Donato M, Dabaja B et al. Total skin electron beam and nonmyeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary yndrome. J Clin Oncol 2010; 28: 2365-2372.
44. Lechowicz MJ, Agovi M, Carreras J et al. Allogeneic hematopoietic cell transplantation (AHCT) for primary cutaneous T cell lymphoma (CTCL): a Center for International Blood and Marrow Transplant Research (CIBMTR) review. Blood 2010; 116: 364 (abstract).
45. Wu PA, Kim YH, Lavori PW et al. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. iol Blood Marrow Transplant 2009; 15: 982-990.